Two students discuss what it takes to move the human story forward!™ ideaXme Ltd.

Successful young scientists and leaders from Canada; Mohit Sodhi, a graduate student at the University of British Columbia, and Mohammad Asadi Lari, an MD/PhD student at the University of Toronto discuss how two movements they started, YNOTFORTOTS and STEM Fellowship help students of all ages to get access to opportunities advancing their careers and lives using the power of critical analysis and scientific reasoning.

Sjaak Vink is the Founder & CEO, TheSocialMedwork, an organization with a mission of “Global health access for everyone”. Ira Pastor, ideaXme longevity and aging ambassador interviews Sjaak Vink to find out more.

The SocialMedwork's mission is to empower patients and doctors globally to access the newest and most innovative medicines that are not yet available within their country of residence but have been approved elsewhere.

How he became interested in science, in genetics.

His technology transfer biotech startup activities.

He talks of his activities in the world of synthetic biology.

He explains his thoughts on the colonization of space, as well as the de-extinction of mammoths, dinosaurs, and neanderthals.

Finally, Professor George Church tells me whom he would like to meet and what he'd like to ask this person/s.

Ira Pastor, ideaXme longevity and aging ambassador and founder of Bioquark interviews Peter de Keizer Assistant Professor Senescence UMC Utrecht and Scientific Founder Cleara Biotech.

Senescent cells remain present in the body and form a prelude to cancer. Evidence indicates that the removal of senescent cells can improve the healthspan of fast aging mice and inhibit cancer progression.

Peter's long-term personal aim is to unravel at a molecular level how cells decide to enter senescence ...

Stephen Spender ideaXme arts ambassador, singer songwriter and actor interviews Gary Burns award winning Canadian writer and director.  They talk of Gary's first dramatic feature film out shortly, advice for future filmmakers and why Gary would like to meet the deceased director John Cassavetes.

Stephen Spender met Gary when he starred in Gary’s first feature film.

Very few of us are taught how to be brave. It is hard to imagine the magnitude of rowing 12 hours a day and being in the middle of the Athletic Ocean with little experience. Amy Jones ideaXme bravery ambassador talks to team Status Row, who rowed 3,000 across the Atlantic Ocean. She finds out how they kept going and what we can all learn from these three women who were so brave to move forward with our lives.

Dr. John LaMattina, was President of Pfizer’s global R&D organization, where he managed more than 13,000 scientists.

He was responsible for many of its" blockbusters" including Lipitor, Viagra, Zoloft, Zithromax, Celebrex, Aricept, Diflucan, and Norvasc which turned Pfizer into the $50+ billion mega-pharma organization.

After Pfizer he moved into to PureTech Ventures where he sits on the board of many start-up and development phase companies in the biotech and health tech space.

Ira Pastor ideaXme longevity and aging ambassador and founder of Bioquark interviews Jahahreeh Finley, a life science patent attorney with a difference! Jahahreeh makes, connections, both intellectual and intuitive to produce powerful scientific breakthroughs in life sciences.

He has recently authored several publications "likely have an immeasurable impact on the assessment of disease ethology".

Ira Pastor ideaXme aging and longevity ambassador investigates Peter Nitschke's work as founder of Exit International and his vision: "That every adult of sound mind has the right to implement plans for the end of their life, so that their death is reliable, peaceful and at a time of their choosing". Nitschke is often referred to as "the Elon Musk of assisted suicide".

Ira Pastor ideaXme longevity and aging ambassador and founder of Bioquark interviews Professor Peter A McNaughton, Kings College London. McNaughton is Professor of Pharmacology, a senior scientist heading a group which aims to discover more about the molecular basis of pain. He heads research projects in several areas plus two drug discovery programmes in which they seek to develop new drugs to inhibit some of the novel targets which have been discovered in their lab.